In fact, TRAIL showed robustly (ICs50 < 10 nM) cytotoxicity in CRC cells, including COLO205, HCT116, and LS174T cells overexpressing DR5 and/or DR4 (Figure 1(C, D)), indicating that TRAIL might overcome the chemotherapeutic MDR of CRC cells. This evidence concerns the gene TNFRSF10A and colorectal carcinoma.